Celen, Mustafa KemalDal, TubaAyaz, CelalBayan, KadimMert, DuyguDeveci, OzcanOruc, Ebru Kursun2024-04-242024-04-2420140353-94661333-9451https://hdl.handle.net/11468/22739Entecavir is a guanosine analogue with activity against hepatitis B virus. The aim of this 4-year trial was to evaluate entecavir treatment in nucleos(t)ide-naive HBeAg-positive chronic hepatitis B patients. Forty-nine patients received entecavir and nine of them withdrew from the trial at the end of week 96. The initial mean value of alanine aminotransferase was 79.4 +/- 41.5 IU/L, and at the end of the 4-year study period, 90% of patients had alanine aminotransferase values within the normal range. At week 96, 91.7% of patients had HBV DNA <300 copies; at month 48, 90% of patients had HBV DNA <50 IU/mL. HBeAg loss was recorded in 7.1% of patients at week 96 and in 12.5% at month 48. The rate of HBeAg seroconversion was 4.8% at week 96 and 7.5% at month 48. The rate of HBsAg seroconversion was 2.1% at week 96 and 2.5% at month 48. Entecavir as a potent and safe agent leading to continuous viral suppression proved to be safe and well tolerated therapy.eninfo:eu-repo/semantics/closedAccessGuanine - Therapeutic UseHepatitis BChronicAntiviral Agents - TherapyArticle5313136WOS:00033721680000524974664Q4